CDK
Os inibidores das quinases dependentes de ciclinas (CDK) são compostos que bloqueiam a atividade das CDKs, um grupo de quinases de proteínas que regulam o ciclo celular, a transcrição e outros processos celulares. As CDKs são ativadas pela ligação às ciclinas, e sua atividade é crucial para a progressão das células através das diferentes fases do ciclo celular. Inibir as CDKs pode interromper a divisão celular, levando à parada do ciclo celular e à apoptose, especialmente em células cancerígenas onde as CDKs frequentemente estão desreguladas. Os inibidores de CDK são amplamente utilizados na pesquisa do câncer e têm potencial terapêutico no tratamento de vários tipos de câncer. Na CymitQuimica, oferecemos uma seleção abrangente de inibidores de CDK de alta qualidade para apoiar sua pesquisa em controle do ciclo celular, câncer e desenvolvimento terapêutico.
Foram encontrados 541 produtos de "CDK"
Ordenar por
Pureza (%)
0
100
|
0
|
50
|
90
|
95
|
100
CDK4/6-IN-5
CAS:CDK4/6-IN-5 inhibits CDK4/6; Ki: 0.2 nM (CDK4/D1) & 4.4 nM (CDK6/D3). (WO2019207463A1, A93)Fórmula:C22H28ClFN6O4SCor e Forma:SolidPeso molecular:527.01Multi-target kinase inhibitor 2
Compound 5K (Multi-target kinase inhibitor 2) is a multi-targeted kinase inhibitor demonstrating activity against EGFR, Her2, VEGFR2, and CDK2 with IC50 valuesPureza:98%Cor e Forma:Odour SolidCDK12-IN-6
CAS:CDK12-IN-6, a pyrazolotriazine, strongly inhibits CDK12 (IC50 1.19 μM at 2 mM ATP), but not CDK2/Cyclin E or CDK9/Cyclin T1 (both IC50 >20 μM).Fórmula:C20H21F2N9Cor e Forma:SolidPeso molecular:425.448TMX-2138
CAS:TMX-2138 is a CDKs PROTAC degrader, with IC50 values of 8.7 nM for CDK1/cyclinB, 10.9 nM for CDK2/cyclinA, 7.0 nM for CDK5/p25, and 25.7 nM for CDK9/cyclinT1. It enhances the ubiquitination and degradation of CDKs and is utilized for ovarian cancer research.Fórmula:C40H43BrFN9O11SCor e Forma:SolidPeso molecular:956.791CDK9 inhibitor HH1
CAS:CDK9 inhibitor HH1 (8019-9719) is an inhibitor of the human CDK2-cyclin A2 complex with an IC50 value of 2 μM.
Fórmula:C13H15N3OSPureza:99.92%Cor e Forma:SolidPeso molecular:261.34NecroIr2
NecroIr2, an iridium(III) compound, induces necroptosis in Cisplatin-resistant A549R lung cancer cells and disrupts mitochondria.Fórmula:C46H30ClIrN6O2Cor e Forma:SolidPeso molecular:926.44XY028-133
CAS:XY028-133 is a PROTAC-based CDK4/6 degrader for the study of tumors.
Fórmula:C53H67N11O7SPureza:97.11%Cor e Forma:SolidPeso molecular:1002.23CDK9-IN-25
CDK9-IN-25 (compound 4a), an imidazopyrazine derivative, functions as a CDK9 inhibitor with an IC50 of 0.24 μM.
Fórmula:C15H16FN5Pureza:98%Cor e Forma:SolidPeso molecular:285.32EGFR/CDK2-IN-2
EGFR/CDK2-IN-2 (compound 6a) serves as a dual inhibitor targeting both EGFR and CDK-2, exhibiting IC50 values of 19.6 nM and 87.9 nM, respectively.Fórmula:C49H32N12O2S2Pureza:98%Cor e Forma:SolidPeso molecular:884.99Cdk2/Cyclin Inhibitory Peptide I
CDK2, a Ser/Thr kinase, is akin to yeast cdc28 and human Cdk1, crucial for cell division.Fórmula:C111H196N48O23Pureza:98%Cor e Forma:SolidPeso molecular:2571.05CDK7-IN-7
CAS:CDK7-IN-7: Selective CDK7 inhibitor, IC50 < 50 nM (Patent CN112661745A).
Fórmula:C20H20BrF3N6O2Cor e Forma:SolidPeso molecular:513.319CDK7-IN-21
CAS:CDK7-IN-21 (compound A22) is a potent CDK7 inhibitor [1] .Fórmula:C33H36FN9O2Cor e Forma:SolidPeso molecular:609.7PROTAC CDK9 degrader-11
CAS:PROTAC CDK9 degrader-11 (Compound C3) is an orally active PROTAC CDK9 degrader with a DC50 of 1.09 nM. This compound exhibits cytotoxicity in small cell lung cancer (SCLC) cells, with IC50 values in the nanomolar range. It induces cell cycle arrest at the G0/G1 phase and inhibits cell invasion in DMS114 and DMS53 cells. In addition, PROTAC CDK9 degrader-11 shows antitumor activity in an NCI-H446 xenograft mouse model. (Pink: ligand for target protein CDK9 ligand 3; Black: linker; Blue: ligand for E3 ligase Cereblon E3 ligase Ligand 56)Fórmula:C39H48Cl2N10O5Cor e Forma:SolidPeso molecular:807.768IV-361
CAS:IV-361, an orally active and selective CDK7 inhibitor with a Ki value of less than or equal to 50 nM, demonstrates potent anti-cancer activity (US20190256531A1Fórmula:C23H32FN5O2SiCor e Forma:SolidPeso molecular:457.625PROTAC CDK9 degrader-8
PROTAC CDK9 Degrader-8 (Compound 21) is a potent degrader of CDK9 with an IC50 of 0.01 μM, utilized in cancer research [1].Fórmula:C44H52Cl2N10O7Pureza:98%Cor e Forma:SolidPeso molecular:903.85CDK12/13-IN-2
CDK12/13-IN-2 (Compound 24) is a covalent inhibitor of CDK12 and CDK13, exhibiting IC50 values of 15.5 nM and 12.2 nM, respectively. It effectively inhibits the proliferation of breast cancer cells and can be utilized in the research of triple-negative breast cancer.Fórmula:C24H22FN7O2Cor e Forma:SolidPeso molecular:459.48EGFR/CDK2-IN-3
EGFR/CDK2-IN-3 (compound 4b) serves as a dual inhibitor targeting both EGFR and CDK-2, exhibiting IC50 values of 71.7 nM and 113.7 nM, respectively.Fórmula:C30H20N6OSPureza:98%Cor e Forma:SolidPeso molecular:512.58CDK9 ligand 3
CAS:CDK9ligand 3 is a ligand for CDK9 and can be utilized in the synthesis of PROTAC degraders, specifically PROTAC CDK9degrader-11.
Fórmula:C18H18BrCl2N5O3Cor e Forma:SolidPeso molecular:503.177CDK2-IN-43
CDK2-IN-43 (Compound 3a) is a CDK2-cyclin E2 inhibitor with an IC50 value of 6.0 nM. It is applicable to cancer research.Fórmula:C19H27N7OCor e Forma:SolidPeso molecular:369.464CDK5-IN-1
CAS:CDK5-IN-1: Potent CDK5 inhibitor (<10 nM) used in kidney disease research.Fórmula:C24H25FN6O3SCor e Forma:SolidPeso molecular:496.56
